Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

11/14/24 11:34:47 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EGRX alert in real time by email

SC 13G/A 1 Eagle_Pharma.txt 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1) * Eagle Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 269796108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1 (b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the ACT but shall be subject to all other provisions of the Act (however, see the Notes). SEC 1745 (3-98) CUSIP No.269796108 1. Names of Reporting Persons. Brandes Investment Partners, L.P. I.R.S. Identification Nos. of above persons (entities only). 33-0704072 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 0 7. Sole Dispositive Power 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 0.00 % 12. Type of Reporting Person (See Instructions) IA, PN CUSIP No.269796108 1. Names of Reporting Persons. CO-GP, LLC I.R.S. Identification Nos. of above persons (entities only). 73-1677697 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 0 7. Sole Dispositive Power 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 shares are deemed to be beneficially owned by CO-GP, LLC as a control person of the investment adviser. CO-GP, LLC disclaims any direct ownership of the shares reported in this Schedule 13G, except for an amount that is substantially less than one per cent of the number of shares reported herein. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 0.00 % 12. Type of Reporting Person (See Instructions) CO, OO (Control Person) CUSIP No.269796108 1. Names of Reporting Persons. Brandes Worldwide Holdings, L.P. I.R.S. Identification Nos. of above persons (entities only). 33-0836630 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 0 7. Sole Dispositive Power 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 shares are deemed to be beneficially owned by Brandes Worldwide Holdings, L.P., as a control person of the investment adviser. Brandes Worldwide Holdings, L.P. disclaims any direct ownership of the shares reported in this Schedule 13G. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 0.00 % 12. Type of Reporting Person (See Instructions) PN, OO (Control Person) CUSIP No.269796108 1. Names of Reporting Persons. Glenn Carlson I.R.S. Identification Nos. of above persons (entities only). 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) 0 (b) 0 3. SEC Use Only 4. Citizenship or Place of Organization USA Number of Shares Beneficially owned by Each Reporting Person With: 5. Sole Voting Power 6. Shared Voting Power 0 7. Sole Dispositive Power 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 shares are deemed to be beneficially owned by Glenn Carlson, a control person of the investment adviser. Mr. Carlson disclaims any direct ownership of the shares reported in Schedule 13G, except for the amount that is substantially less than one per cent of the number of shares reported herein. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 0 11. Percent of Class Represented by Amount in Row (9) 0.00 % 12. Type of Reporting Person (See Instructions) IN, OO (Control Person) Item 1(a) Name of Issuer: Eagle Pharmaceuticals Inc. Item 1(b) Address of Issuers Principal Executive Offices: 50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ 07677 Item 2(a) Name of Person Filing: (i) Brandes Investment Partners, L.P. (ii) CO-GP, LLC. (iii) Brandes Worldwide Holdings, L.P. (iv) Glenn Carlson Item 2(b) Address of Principal Business office or, if None, Residence: (i) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (ii) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (iii) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 (iv) 4275 Executive Square, 5th Floor, La Jolla, CA 92037 Item 2(c) Citizenship (i) Delaware (ii) Delaware (iii) Delaware (iv) USA Item 2(d) Title of Class Securities: Common Shares Item 2(e) CUSIP Number: 269796108 Item 3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(ii)(F). (g) [ ] A parent holding company or control person in accordance with 240.13d- 1(b)(1)(ii)(G). (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). (j) [x] Group, in accordance with 240.13d- 1(b)(1)(ii)(J). This statement is filed by Brandes Investment Partners, L.P., an investment adviser registered under the Investment Advisers Act of 1940, its control persons and its holding company. (See, also, Exhibit A.) Item 4. Ownership: (a) Amount Beneficially Owned: 0 (b) Percent of Class: 0.00 % (c) Number of shares as to which the joint filers have: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ?. N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. See Exhibit A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification: (a) The following certification shall be included if the statement is filed pursuant to 240.13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 5, 2024 BRANDES INVESTMENT PARTNERS, L.P. By: /s/ Glenn Carlson Glenn Carlson, General Partner CO-GP, LLC its General Partner CO-GP, LLC By: /s/ Glenn Carlson Glenn Carlson, General Partner BRANDES WORLDWIDE HOLDINGS, L.P. By: /s/ Glenn Carlson Glenn Carlson of CO- GP, LLC its General Partner By: /s/ Glenn Carlson Glenn Carlson, Control Person EXHIBIT A Identification and Classification of Members of the Group Pursuant to Rule 13d-1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, the members of the group making this joint filing are identified and classified as follows: Name Classification Brandes Investment Partners, L.P. (the Investment Adviser) Investment adviser registered under Investment Advisers Act of 1940 Co-GP, LLC A control person of the Investment Adviser Brandes Worldwide Holdings, L.P. A control person of the Investment Adviser Glenn Carlson A control person of the Investment Adviser EXHIBIT B Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d- 1(b)(ii)(J) and Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the Act) by and among the parties listed below, each referred to herein as a Joint Filer. The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1. Dated: November 5, 2024 BRANDES INVESTMENT PARTNERS, L.P. By: /s/ Glenn Carlson Glenn Carlson, General Partner of Co-GP, LLC. Co-GP, LLC. By: /s/ Glenn Carlson Glenn Carlson, General Partner EXHIBIT C Disclaimer of Beneficial Ownership Co-GP, LLC, Brandes Worldwide Holdings, L.P., and Glenn Carlson disclaim beneficial interest as to the shares referenced above, except for an amount equal to substantially less than one percent of the shares reported on this Schedule 13D. None of these entities or individuals holds the above-referenced shares for its/his own account except on a de minimis basis. /s/Glenn Carlson Glenn Carlson

Get the next $EGRX alert in real time by email

Date

Price Target

Rating

Analyst

8/10/2023

$26.00 → $17.00

Neutral → Underweight

Piper Sandler

8/9/2023

$26.00 → $17.00

Neutral → Underweight

Piper Sandler

Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for
$EGRX

$EGRX
Press Releases

Fastest customizable press release news feed in the world

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

$EGRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.